Xenical (orlistat) / Roche, GSK - LARVOL DELTA

Glucagon-Like Peptide 1 Receptor Agonists and Venous Thromboembolism in Patients with Obesity (ISTH 2025) - "In two separate analyses, we compared patients receiving GLP1-RAs with other approved anti-obesity medications (including orlistat, phentermine) and GLP1-RAs with bariatric surgery (BSurg). In contrast, the risks of VTE (HR, 1.25 [95% CI: 0.95-1.64]) as well as PE or DVT with GLP1-RAs and BSurg did not differ significantly (Figure 2). Table or Figure Upload"

Clinical • Atrial Fibrillation • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Oncology • Respiratory Diseases • Type 2 Diabetes Mellitus • Venous Thromboembolism

Elevated BMI and Antiobesity Medication Prevalence in Adults with Type 1 Diabetes—Cross-Sectional Study of the Epic Cosmos Database (ADA 2025) - "We queried prevalence of: 1) BMI 27 to <30 kg/m2, or ≥30 kg/m2, and 2) active AOM's: phentermine, semaglutide, tirzepatide, liraglutide, orlistat, phentermine/topiramate, and naltrexone/bupropion. In 2017, 20.1% had BMI 27 to <30 kg/m2 and 27.5% had BMI ≥ 30 kg/m2. Overweight/obesity was common in this cohort. Although AOM use increased, a small portion of adults with BMI ≥ 27 kg/m2 are receiving treatment. Further study of anti-obesity medication safety and efficacy in people with T1D is needed."

Clinical • Late-breaking abstract • Observational data • Diabetes • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus

Enhancing Glycemic Control through Orlistat Combination Therapy with Pioglitazone and Metformin in Patients with Obesity Type 2 Diabetes—A Multicenter Randomized Controlled Trial (ADA 2025) - "Orlistat is effective for patients with obesity and type 2 diabetes who are receiving pioglitazone-metformin therapy, it reduces body weight, improves fat distribution, alleviates insulin resistance, and enhances glycemic control."

Clinical • Combination therapy • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Erica spiculifolia Salisb. (Balkan Heath): A Focus on Metabolic Profiling and Antioxidant and Enzyme Inhibitory Properties. (PubMed, Plants (Basel)) - "Chlorogenic acid and proanthocyanidin tetra- and trimer A, B-type together with quercitrin and (+) catechin were the predominant compounds in the semi-quantitative analysis...It exhibited prominent anti-lipase (18.32 mg orlistat equivalents/g) and anti-tyrosinase (71.90 mg kojic acid equivalents/g) activity. The extract inhibited α-glucoside (1.35 mmol acarbose equivalents/g) and acetylcholinesterase (2.56 mg galanthamin equivalents/g), and had moderate effects on α-amylase, elastase, collagenase and hyaluronidase. Balkan heath could be recommended for raw material production with antioxidant and enzyme inhibitory properties."

Journal • ELANE • Tyrosinase

Combined Potential of Orlistat with Natural Sources and Their Bioactive Compounds Against Obesity: A Review. (PubMed, Molecules) - "This approach aims to enhance the inhibition of pancreatic lipase and other obesity-related markers, thereby improving therapeutic outcomes and reducing adverse effects associated with treatment. The objective of this review is to analyze the available scientific evidence regarding the combined effects of orlistat and extracts or bioactive compounds in inhibiting various markers related to dyslipidemia and obesity, with the goal of proposing combination therapy as a safe and effective therapeutic option."

Journal • Review • Dyslipidemia • Genetic Disorders • Metabolic Disorders • Obesity

Endothelial lipase facilitates low-density lipoprotein (LDL) uptake in LDL receptor deficiency by a heparan sulfate proteoglycan-dependent mechanism. (PubMed, bioRxiv) - "Finally, tetrahydrolipstatin was used to inhibit EL enzymatic activity in uptake studies...Our data reveals that EL facilitates the uptake of LDL in hepatocytes through an LDLR-independent, HSPG-dependent pathway that involves EL's enzymatic activity. This pathway provides an additional mechanism to explain the reduction of LDL cholesterol induced by ANGPTL3 inhibitors and represents a potential druggable target to treat FH."

Journal • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Metabolic Disorders • ANGPTL3 • LDLR

Development of new Magnetic Resonance Imaging and Spectroscopy techniques to diagnose fat malabsorption (ECFS 2025) - "They were asked to take a dose of lipase inhibitor orlistat (120 mg) or placebo with each meal, MRI and MRS were taken 2h after the last high-fat meal... MRI and MRS could potentially be used as a new method to identify FM, reducing the burden of care and improving patient experiences in CF. This preliminary use of MRS techniques to assess fat spectra from the colonic chyme is novel and further work is needed to improve spectral quantification of fat."

MRI • Cystic Fibrosis • Gastrointestinal Disorder • Genetic Disorders • Immunology • Respiratory Diseases

Efficacy of Orlistat in type 2 diabetes - a systematic review and meta analysis. (PubMed, BJGP Open) - "Orlistat resulted in statistically significant greater weight loss in overweight adults with T2DM/high risk compared with controls. Orlistat can be considered an adjunct in T2DM/high risk of T2DM for weight loss along with diet/lifestyle modifications."

Journal • Retrospective data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Anti-obesity effects of superparamagnetic iron oxide nanoparticles mediated through modulation of hepatic lipolysis and mitochondrial biogenesis. (PubMed, Gene) - "The anti-obesity effects of SPIONs may be mediated by inducing many pathways such as insulin-sensitizing, lipotropic, antioxidant, anti-lipogenic, and mitochondrial biogenesis. More importantly, the adjuvant treatment with orlistat may potentiate the effects of SPION and neglect the use of high SPION doses."

Journal • Genetic Disorders • Obesity • NFE2L2 • NRF1

Umbrella Review of Pharmacological interventions on Metabolic and Endocrine Outcomes in Women with PCOS (ENDO 2025) - "The search spanned from Jan 1st, 1980, to January 5th, 2024, focusing on pharmacological interventions (Metformin, GLP-1, SGLT-2 inhibitors, statins, sitagliptin, pioglitazone, orlistat)...Combined therapy with simvastatin and metformin reduced LH: FSH compared to metformin monotherapy (n=2, N=219, SMD= -2.66,95% CI: [-3.02; -2.29], p= 0.36, I2=0%)... This review highlights the effectiveness of monotherapy, combined therapy, and new type 2 diabetes drugs in PCOS management. GLP-1s exhibit evidence in weight management and mitigating cardiometabolic risks. SGLT-2 inhibitors demonstrate potential in reducing hyperglycaemia, hyperandrogenism, and cardiovascular risks."

Clinical • Review • Cardiovascular • Diabetes • Metabolic Disorders • Polycystic Ovary Syndrome • Type 2 Diabetes Mellitus

Umbrella Review of Pharmacological interventions on Metabolic and Endocrine Outcomes in Women with PCOS (ENDO 2025) - "The search spanned from Jan 1st, 1980, to January 5th, 2024, focusing on pharmacological interventions (Metformin, GLP-1, SGLT-2 inhibitors, statins, sitagliptin, pioglitazone, orlistat)...Combined therapy with simvastatin and metformin reduced LH: FSH compared to metformin monotherapy (n=2, N=219, SMD= -2.66,95% CI: [-3.02; -2.29], p= 0.36, I2=0%)... This review highlights the effectiveness of monotherapy, combined therapy, and new type 2 diabetes drugs in PCOS management. GLP-1s exhibit evidence in weight management and mitigating cardiometabolic risks. SGLT-2 inhibitors demonstrate potential in reducing hyperglycaemia, hyperandrogenism, and cardiovascular risks."

Clinical • Review • Cardiovascular • Diabetes • Metabolic Disorders • Polycystic Ovary Syndrome • Type 2 Diabetes Mellitus

Rising Above the Rest: Worldwide Trends in Public Interest for Semaglutide Among Weight Loss Alternatives (ENDO 2025) - "Glucagon-like peptide-1 receptor agonists, including semaglutide and liraglutide, as well as the newly approved dual GLP-1/GIP receptor agonist tirzepatide, have proven highly effective in achieving weight loss. Semaglutide is the rising star among weight loss methods, establishing more public interest than any other in 2024. Public policy should address its newfound popularity and the implications it entails, like the possible surge in demand and limited availability for previous indications like glucose control."

Gastrointestinal Disorder • Genetic Disorders • Obesity

A case report of hyperchylomicronemia and recurrent pancreatitis in a patient with the pArg333His variant of the lipoprotein lipase gene (NLA 2025) - "Dietary control, collaboration with a nutritionist, and Orlistat have been successful...The patient has maintained triglyceride levels below 400 mg/dL and no further episodes of pancreatitis. The novel p.His71Gln variant warrants further investigation to clarify its role in the pathogenesis of multifactorial chylomicronemia syndrome."

Case report • Clinical • Dyslipidemia • Hypertriglyceridemia • Pancreatitis • Severe Hypertriglyceridemia • LPL

From Obesity to Fertility: A Systematic Review of Pharmacological and Surgical Treatments and Reproductive Outcomes (ECO 2025) - "Metformin and orlistat, assessed in 10 studies, achieved modest weight loss (3-5 kg) and ovulation rates of 30%-52%. Pharmacological treatments improve reproductive outcomes in individuals with obesity or overweight, with GLP-1 receptor agonists showing significant efficacy. The limited reporting of pregnancy and live birth outcomes highlights the need for more robust research. New therapies, like tirzepatide, warrant exploration to advance the management of obesity-related infertility."

Review • Diabetes • Genetic Disorders • Infertility • Obesity • Polycystic Ovary Syndrome • Sexual Disorders • Type 2 Diabetes Mellitus

Clinical and preclinical relevance of postbiotic pA1c®HI in obesity management (ECO 2025) - " In C. elegans, pA1c®HI significantly reduces fat storage (-21.2±5.0% vs control) and the magnitude of the reduction in the lipid content was similar (p ≥ 0.05) to the anti-obesity drug Orlistat... The postbiotic pA1c®HI supplementation reduces fat accumulation, BMI, fat mass, and increases lean mass. The modulation of lipid metabolism-related genes, enhanced GLP-1 secretion, inhibited leptin and microbiota modulation are implicated in the mechanism of action. These findings suggest its potential as a novel alternative for the nutritional management of obesity and improving lipid metabolic health."

Preclinical • Genetic Disorders • Obesity • CD36 • LEP • SCARB1

Detection of disease on nasal breath sound by new lightweight architecture: Using COVID-19 as an example. (PubMed, Digit Health) - "The proposed model achieved 97% accuracy in detecting COVID-19 from nasal breathing sounds, outperforming state-of-the-art methods such as those by Lella and Alphonse and Abayomi-Alli et al...The findings suggest that the proposed method holds significant potential for clinical implementation, advancing smartphone-based diagnostics in infectious diseases. The Dense-ReLU-Dropout model, combined with innovative feature processing techniques, offers a promising approach for efficient and accurate COVID-19 detection, showcasing the capabilities of mobile device-based diagnostics."

Journal • Infectious Disease • Novel Coronavirus Disease • Otorhinolaryngology • Respiratory Diseases

Efficacy and Safety of Pharmacological Interventions in Managing Cardiometabolic Risk Factors in Youth Living with Overweight and Obesity: A Systematic Review and Network Meta-Analysis. (PubMed, Obes Rev) - "High- and moderate-dose phentermine/topiramate was more effective than a placebo in reducing anthropometric measures in youth living with overweight and obesity. Liraglutide and metformin result in a significant reduction in FBG levels compared to placebo."

Clinical • Journal • Retrospective data • Review • Genetic Disorders • Obesity

Protective Effects of a Standardized Water Extract from the Stem of Ipomoea batatas L. Against High-Fat Diet-Induced Obesity. (PubMed, Nutrients) - "The mice were then treated orally with either orlistat (positive control) or WIB...These findings suggest that WIB may serve as a promising natural substance for the management of obesity. Further studies are warranted to confirm its efficacy and explore the potential underlying mechanisms in overweight or obese humans as a health supplement to help manage or prevent obesity."

Journal • Genetic Disorders • Obesity • AMPK • PPARA • SIRT1 • SREBF1

Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review. (PubMed, Diseases) - "This narrative review explores established and emerging pharmacotherapies for weight management, including parenteral agents like Liraglutide, Semaglutide, Setmelanotide, and Tirzepatide, as well as peroral medications such as Phentermine, Phentermine/Topiramate, Bupropion/Naltrexone, Orlistat, and Metformin. Newer treatments like Cagrilintide and Bimagrumab show promise for enhancing weight loss outcomes...This includes exploring how AI can complement combination therapies and tailor personalized interventions, thereby grounding its potential benefits in robust clinical evidence. Future directions will focus on integrating AI into clinical trials to refine and personalize obesity management strategies."

Journal • Review • Genetic Disorders • Obesity

Combining kinetics and in silico approaches to evaluate bromhexine as an anti-pancreatic lipase agent for obesity management. (PubMed, Sci Rep) - "Currently, the only clinically approved pharmacological agent for pancreatic lipase inhibition is Orlistat. Collectively, our findings suggest that Bromhexine displays potent pancreatic lipase (PL) inhibition activity and could serve as a potential candidate in weight management as demonstrated by both in silico and in vitro analyses. However, further investigations, including structure-activity relationship (SAR) analyses and in vivo studies, are necessary to confirm its clinical potential as a pancreatic lipase inhibitor."

Journal • Genetic Disorders • Obesity

Promising pancreatic lipase inhibitory activity of a novel tetrapeptide isolated from endophytic Fusarium incarnatum. (PubMed, World J Microbiol Biotechnol) - "Binding energies for triacyl glyceride, Orlistat and compound 1 was found to be -4.8 kcal/mol, -4.9 kcal/mol and - 5.6 kcal/mol respectively. Thus, this novel tetrapeptide holds promise for clinical evaluation since it exhibits a better inhibition profile than the current anti-obesity drug Orlistat."

Journal • Genetic Disorders • Obesity

Synthesis, characterization, and in vitro hypolipidemic mechanisms of sugar-SA triazole conjugates as potent pancreatic lipase inhibitors. (PubMed, Food Chem) - "Among these, the glucose conjugate (GS) exhibited the most potent pancreatic lipase (PL) inhibition, surpassing orlistat, and significantly improved cholesterol and bile salt binding...Molecular docking confirmed strong interactions between GS and key catalytic residues, rationalizing its superior efficacy. The findings highlight the potential of GS as a novel lipid-lowering therapeutic or functional food ingredient targeting obesity and metabolic disorders."

Journal • Preclinical • Genetic Disorders • Metabolic Disorders • Obesity

Comprehensive Obesity Treatment: Moving Beyond Lifestyle Change by Integrating Pharmacotherapy Into Your Practice (APA 2025) - "Commonly prescribed medications, such as antidepressants (e.g., mirtazapine, amitriptyline) and antihyperglycemics (e.g., glyburide, insulin) cause weight gain, and clinicians should review and consider alternatives...Compared to placebo, orlistat was associated with 3.1% greater weight loss, phentermine-topiramate was associated with 8.0% greater weight loss, naltrexone-bupropion was associated with 4.1% greater weight loss, liraglutide was associated with 4.7% greater weight loss, semaglutide was associated with 11.4% greater weight loss and tirzepatide 15 mg was associated with 12.4% greater weight loss...AOMs are effective adjunctive therapy to lifestyle changes for improved health outcomes. Instructional Level Introductory; Learning Objectives Objective One: Understand the principles of chronic weight management to treat obesity and weight-related complications Objective Two: Identify medications that promote weight gain and guide patient consideration of..."

Cardiovascular • CNS Disorders • Constipation • Depression • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hypertension • Metabolic Disorders • Mood Disorders • Obesity • Psychiatry • Type 2 Diabetes Mellitus

Transcutaneous auricular vaguas nerve stimulation promotes adipose tissue browning and mitochondrial integrity by regulating BCAA metabolism in obese rats: an experimental study. (PubMed, Int J Surg) - "In this study, six weeks of taVNS significantly reduced body weight gain, body mass index, and the accumulation of inguinal and epididymal white adipose tissue in high-fat diet (HFD)-induced obese rats, with effects comparable to those of orlistat...We conclude that the anti-obesity effects of taVNS are closely related to BCAA metabolism in BAT. These findings highlight taVNS as a promising approach for obesity management, though further studies are needed to clarify the neurobiological pathways involved and advance taVNS technology."

Journal • Preclinical • Genetic Disorders • Obesity

Knockdown of PGM1 enhances anticancer effects of orlistat in gastric cancer under glucose deprivation (IGCC 2025) - No abstract available

Gastric Cancer • Oncology • Solid Tumor